Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Lignende værker

• Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
  af: Yin, Ophelia Q, et al.
  Udgivet: (2012)
• Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
  af: Jabbour, Elias, et al.
  Udgivet: (2012)
• Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
  af: Kantarjian, Hagop M., et al.
  Udgivet: (2021)
• Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
  af: Hochhaus, Andreas, et al.
  Udgivet: (2013)
• Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
  af: Hughes, Timothy P., et al.
  Udgivet: (2014)